Figure 3. Progression-free survival (PFS) of all patients (A), patients treated with Disitamab Vedotin combined with ICIs and Disitamab Vedotin alone (B), patients with different expression levels of HER2 (C), and patients with urinary cancer and other types of cancer (D).